Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1

The DOI matches its Crossref record.

Cancer surveillance in adults with germline TP53 pathogenic variants: A single-center observational study.

Meyskens, Thomas, Vandecaveye, Vincent, Pans, Steven, Dresen, Raphaëla, Van Ongeval, Chantal, Smeets, Ann, Nevelsteen, Ines, Neven, Patrick, Wildiers, Hans, Schoffski, Patrick, Denayer, Ellen, Van Buggenhout, Griet, Michils, Geneviève, Brems, Hilde, Legius, Eric, Punie, Kevin·2021·Journal of Clinical Oncology

Abstract

10530 Background: Germline pathogenic variants (PV) in the tumor suppressor gene TP53 are associated with a high risk of developing diverse malignancies, often at young age, and predispose to Li-Fraumeni syndrome (LFS). Surveillance programs for presymptomatic PV carriers have shown survival benefit in a non-randomized trial. Here we describe the surveillance findings and clinical outcomes of adults with TP53 PV undergoing a standardized screening protocol. Methods: We identified adults with germline PV in TP53 who underwent surveillance at the University Hospitals Leuven, Belgium, between 04/2013 and 08/2020. Patients with prior cancer were allowed, while patients with an active malignancy requiring treatment at diagnosis of the TP53 PV were excluded. Surveillance was performed per modified Toronto protocol, including annual whole body diffusion-weighted MRI (WB-DWI/MRI), brain MRI, abdominal ultrasound (US), endoscopic surveillance, laboratory tests, dermatological examination and breast MRI/US in females. The primary aim was to evaluate the number and type of malignancies and premalignant lesions diagnosed during screening and to assess the proportion of malignancies detected by surveillance. Secondary outcomes were the cancer detection rate during the first year of screening, the proportion of carriers with false-positive findings, and overall survival. Results: We included 42 adults from 20 apparently unrelated families. Median age was 38y (range, 17-70y) and 23 had a history of prior cancer. After a median follow-up of 41.5mo, we diagnosed 18 cancers in 12/42 participants (29%). Overall survival was 95% in all participants, including 2 carriers who opted to discontinue surveillance. Surveillance detected 10/18 cancers (56%), the majority of whom through WB-DWI/MRI (6/10; 60%). No malignancies were identified with brain MRI. In 5/42 individuals (12%), surveillance detected a malignancy during the first year of screening. Only 2/10 cancers discovered with surveillance (1 soft tissue and 1 bone sarcoma) belong to the LFS core tumors. Cancers not detected with surveillance (8/18) were 6 non-melanoma skin cancers and 2 interval cancers (sarcoma post radiation, secondary acute leukemia). Additionally, we detected 27 premalignant lesions in 11/42 patients (26%), of whom 78% were diagnosed by colonoscopy. False-positive findings occurred in 7/42 patients (17%) and were mostly seen with WB-DWI/MRI. Conclusions: Adults with germline PV in TP53 that undergo surveillance have high cancer detection rates. The majority of malignancies were asymptomatic at diagnosis and detected with WB-DWI/MRI. Despite the high cancer incidence, few LFS core cancers were diagnosed and survival was encouraging. Increased genetic testing changes the clinical picture of germline TP53 carrier populations, justifying the transition from LFS to a wider concept of heritable TP53-related cancer syndrome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2021.39.15_suppl.10530

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 1

Metadata

Authors
Meyskens, T., Vandecaveye, V., Pans, S., Dresen, R., Van Ongeval, C., Smeets, A., Nevelsteen, I., Neven, P., Wildiers, H., Schoffski, P., Denayer, E., Van Buggenhout, G., Michils, G., Brems, H., Legius, E., & Punie, K.
Affiliations
  • Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium;
  • Department of Radiology, University Hospitals Leuven, Leuven, Belgium;
  • Department of Surgical Oncology and Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium;
  • Department of Gynaecology & Obstetrics and Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium;
  • Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium;
  • Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium;
Venue
Journal of Clinical Oncology
Published
2021-05-20
Volume
39
Issue
15_suppl
Pages
10530-10530
ISSN
  • 0732-183X
  • 1527-7755
Cited by
1
References
0
Language
en
Funders
None

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer surveillance in adults with germline TP53 pathogenic variants: A single-center observational study. https://app.cochat.ai/papers/10.1200/jco.2021.39.15_suppl.10530
The paper
Meyskens, T., Vandecaveye, V., Pans, S., Dresen, R., Van Ongeval, C., Smeets, A., Nevelsteen, I., Neven, P., Wildiers, H., Schoffski, P., Denayer, E., Van Buggenhout, G., Michils, G., Brems, H., Legius, E., & Punie, K. (2021). Cancer surveillance in adults with germline TP53 pathogenic variants: A single-center observational study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2021.39.15_suppl.10530

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.